Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Allogene Therapeutics (Nasdaq: ALLO) will report Q1 2026 financial results and provide a business update on May 13, 2026 after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Allogene Therapeutics (Nasdaq: ALLO) will report Q1 2026 financial results and provide a business update on May 13, 2026 after market close. A live audio webcast and conference call are scheduled for 2:00 p.m. PT / 5:00 p.m. ET.
Investors can listen via the company's website under Investors > News and Events. A replay will be available for approximately 30 days. Registered participants who wish to ask questions will receive a personal PIN to access the call.
Details
News Market Reaction – ALLO
On May 6, the day this news came out, ALLO closed 6.45% above the previous close.
Data tracked by StockTitan Argus for the May 6 session.
Key Figures
- Current price
- $2.17
- As of last close before Q1 2026 earnings-date announcement
- Price change 24h
- -3.98%
- Move in prior session before this news
- 52-week range
- $0.8621 – $4.46
- Positioned 151.71% above low and 51.35% below high
- Market cap
- $779,755,033
- Equity value prior to Q1 2026 results date announcement
- Earnings call time
- 2 p.m. PT / 5 p.m. ET
- Scheduled for May 13, 2026 webcast and conference call
- Replay duration
- 30 days
- Approximate period webcast replay remains available
- Reporting date
- May 13, 2026
- First quarter 2026 financial results and business update
- Relative volume
- 0.33x
- Today’s 5,787,098 shares vs 20-day average 17,445,284
Previous Earnings date Reports
-
Set date and time for Q4 and full-year 2025 results and webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
allogeneic car t medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will report the first quarter 2026 financial results and provide a business update on May 13, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2 p.m. PT/5 p.m. ET.
Listen-Only Webcast
The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.
Conference Call Registration
If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on X (formerly Twitter) and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Form 10-K filed for the year ended December 31, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.